# Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients

> **NCT07648940** · PHASE1 · COMPLETED · sponsor: **Zodiac Produtos Farmaceuticos S.A.** · enrollment: 74 (actual)

## Conditions studied

- Advanced Ovarian Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Doxopeg® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL)
- **DRUG:** Caelyx® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL)

## Key facts

- **NCT ID:** NCT07648940
- **Lead sponsor:** Zodiac Produtos Farmaceuticos S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-13
- **Primary completion:** 2023-06-22
- **Final completion:** 2023-06-22
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07648940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07648940, "Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07648940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*